Evaluation of gastrointestinal toxicity of ibuprofen using surrogate markers in rats: Effect of formulation and route of administration

Clinical and Experimental Rheumatology

Volumn 18, Issue 2, 2000, Pages 187-192

  Khazaeinia, T ^a   Jamali, F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

GI toxicity; Ibuprofen; NSAID; Permeability

Indexed keywords

IBUPROFEN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFECT; DRUG FORMULATION; GASTROINTESTINAL TOXICITY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CELL MEMBRANE PERMEABILITY; CHROMIUM RADIOISOTOPES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; EDETIC ACID; GASTRIC MUCOSA; IBUPROFEN; INTESTINAL MUCOSA; MALE; RATS; RATS, SPRAGUE-DAWLEY; SUCROSE;

EID: 0034031338     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. STEWARTSA: The propionic acids: A personal perspective. J Clin Pharmacol 1992; 32: 317-23.
2. SCHOEN RT, REES WD: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1988; 84 (Suppl. 2A): 25-34.
3. MEDDINGS JB, KIRCK D, MERLE E, OLSON DVM: Noninvasive detection of nonsteroidal anti-inflammatory drug-induced gastropathy in dogs. Am J Vet Res 1995; 56: 977-81.
4. FORD J, MARTIN W, HOUSTON JB: Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat. J Pharmacol Toxicol Met 1995; 34: 9-16.
5. BJARNASON I, HAYLLAR J, MACPHERSON AJ, RUSSEL AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
6. MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1993; 90: 11693-7.
7. GEISSLINGER G, DIETZEL K, BEZLER H, NURENBURG B, BRUNE K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Tox 1989; 27: 324-8.
8. MARTIN W, KOSELOWSKE G, TOBERICH H, KERKMANN TH. MANGOLD B, AUGUSTIN J: Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopahrm Drug Dispos 1990; 11: 265-78.
9. DAVIES NM, JAMALI F: Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: Evidence of shift in the toxicity site. Pharm Res 1997; 14: 1597-1600.
10. VAKILY M, KHORASHEH F, JAMALI F: Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: A novel pharmacokinetic-pharmacodynamic model. Pharm Res 1999; 16: 123-9.
11. HALTER F, WEBER B, HUBERT, EIGENMANN F, FREY MP, RUCHTI C: Diaphragm disease of the ascending colon. Association with sustained-release diclofenac. J Clin Gastroenterol 1993; 16: 74-80.
12. FIGUERAS A, CAPELLA D, CASTEL JM, LAPORTE JR: Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 1994; 47: 297-303.
13. DAVIES NM, CORRIGAN BW, JAMALI F: Sucrose urinary excretion in the rat measured using a simple assay: A model of gastroduodenal permeability. Pharm Res 1995; 12: 1733-6.
14. DAVIES NM, WRIGHT MR, JAMALI F: Anti-inflammatory drug induced small intestinal permeability: The rat is a suitable model. Pharm Res 1994; 11: 1652-6.
15. SATTARI S, JAMALI F: Evidence of absorption rate dependency of ibuprofen inversion in the rat. Chirality 1994; 6: 435-9.
16. SHANBHAG V R, CRIDER AM, GOKHALE R, HARPALANI, DICK RM: Ester and amide pro-drugs of ibuprofen and naproxen: Synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J Pharmaceut Sci 1992, 81: 149-54.
17. INMAN WHW, WILYON LV, PEARCE GL, WALLER PC: Prescription-event monitoring of nabumetone. Pharmaceut Med 1990; 4: 309-17.
18. DANDONA P, JEREMY JY: Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? Drugs 1990; 40 (Suppl.): 16-24.
19. SIMON LS, ZHAO SZ, ARGULLES LM et al.: Economic and gastrointestinal safety comparisons of etodolac, nambutone, and oxprozin from insurance claims data from patients with arthritis. Clin Ther 1998; 20: 1218-35.
20. HOFTIEZER JW, SILVOSO GR, BURKS M, IVEY KJ: Comparison of the effects of regular and enteric-coaled aspirin on gastroduodenal mucosa of man. Lancet 1980; 2: 609-12.
21. TRONDSTAD RI, AADLLAND E, HOLLER T, OLAUSSEN B: Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol 1985; 20: 239-42.
22. DAYTK: Intestinal perforation associated with osmotic slow release indomethacin capsules. Br Med J 1983; 287: 1671-2.
23. 51Cr-labelled erythrocytes. Scand J Rheumatol 1989; 18: 307-13.
24. AABAKKEN L, BYORNBETH BA, HOFSTAD B, OLAUSSEN B, LARSEN S, OSNES M: Comparison of gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules. Scand J Gastroenterol 1989; 24 (Suppl. 163): 65-73.
25. CHOI VMF, COATES JE, CHOSI J, THOMSON ABR, RUSSEL AS: Small bowel permeability -A variable effect of NSAIDs. Clin Invest Med 1995; 18: 357-61.